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Abstract
Background: Xenorhabdus spp. live in close symbiosis with nematodes of the Steinernema genus. Steinernema
nematodes infect an insect larva and release their symbionts into the haemocoel of the insect. Once released into
the haemocoel, the bacteria produce bioactive compounds to create a semi-exclusive environment by inhibiting
the growth of bacteria, yeasts and molds. The antimicrobial compounds thus far identified are xenocoumacins,
xenortides, xenorhabdins, indole derivatives, xenoamicins, bicornutin and a number of antimicrobial peptides. The
latter may be linear peptides such as the bacteriocins xenocin and xenorhabdicin, rhabdopeptides and cabanillasin,
or cyclic, such as PAX lipopeptides, taxlllaids, xenobactin and szentiamide. Thus far, production of antimicrobial
compounds have been reported for Xenorhabdus nematophila, Xenorhabdus budapestensis, Xenorhabdus cabanillasii,
Xenorhabdus kozodoii, Xenorhabdus szentirmaii, Xenorhabdus doucetiae, Xenorhabdus mauleonii, Xenorhabdus indica
and Xenorhabdus bovienii. Here we describe, for the first time, PAX lipopeptides and xenocoumacin 2 produced by
Xenorhabdus khoisanae. These compounds were identified using ultraperformance liquid chromatography, linked to
high resolution electrospray ionisation mass spectrometry and tandem mass spectrometry.
Results: Cell-free supernatants of X. khoisanae SB10 were heat stable and active against Bacillus subtilis subsp.
subtilis, Escherichia coli and Candida albicans. Five lysine-rich lipopeptides from the PAX group were identified in
HPLC fractions, with PAX1’ and PAX7 present in the highest concentrations. Three novel PAX7 peptides with
putative enoyl modifications and two linear analogues of PAX1’ were also detected. A small antibiotic compound,
yellow in colour and λmax of 314 nm, was recovered from the HPLC fractions and identified as xenocoumacin 2. The
PAX lipopeptides and xenocoumacin 2 correlated with the genes and gene clusters in the genome of X. khoisanae
SB10.
Conclusion: With UPLC-MS and MSe analyses of compounds in the antimicrobial complex of X. khoisanae SB10, a
number of PAX peptides and a xenocoumacin were identified. The combination of pure PAX1’ peptide with
xenocoumacin 2 resulted in high antimicrobial activity. Many of the fractions did, however, contain labile compounds
and some fractions were difficult to resolve. It is thus possible that strain SB10 may produce more antimicrobial
compounds than reported here, as suggested by the APE Ec biosynthetic complex. Further research is required to
develop these broad-spectrum antimicrobial compounds into drugs that may be used in the fight against microbial
infections.
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Background
Xenorhabdus bacteria are in a species-specific associ-
ation with Steinernema nematodes, i.e. a specific Steiner-
nema sp. is associated with a specific Xenorhabdus sp.
[1]. At the beginning of the Xenorhabdus-Steinernema
life cycle, nematodes in the infective juvenile phase in-
fect the insect host by entering the mouth, anus or re-
spiratory spiracles [2]. Once inside the insect, the
nematodes release the symbiotic bacteria by defecation.
Steinernema nematodes produce proteins that suppress
the insect’s immune response, which allows Xenorhab-
dus to multiply [3]. The release of exoenzymes and
toxins by both mutualists leads to septicaemia and the
insect dies within 24 to 48 h after infection [4–6]. Nema-
todes reproduce sexually by going through phases J1 to
J4 until resources are depleted, after which they return
to the infective juvenile state, acquire symbionts and
leave the cadaver in search of a new host.
During the nematode life cycle, Xenorhabdus spp. pro-
duce various compounds to create a semi-exclusive en-
vironment and prevent colonisation of the host (insect)
by other microorganisms [7]. Dutky [8] was the first to
suggest that Xenorhabdus produce antimicrobial com-
pounds. However, interest in these antimicrobial com-
pounds only gained momentum 22 years later [9].
Numerous bioactive compounds have since then been
detected in the cell-free supernatants of Xenorhabdus
spp., including broad-spectrum compounds with activity
against bacteria, fungi, insects, nematodes, protists and
cancer cells. These compounds range from being small
antibiotics, such as xenocoumacins [10], xenortides [11],
xenorhabdins [12] and indole derivatives [13], to larger,
more complex, compounds such as xenoamicins [14],
bicornutin [15] and various antimicrobial peptides
(AMPs). Some AMPs are cyclic, such as PAX (peptide-
antimicrobial-Xenorhabdus) lipopeptides [16], taxlllaids
[17], xenobactin [18] and szentiamide [19], while others
are linear, such as rhabdopeptides [20], cabanillasin [21]
and bacteriocins. Thus far, xenocin and xenorhabdicin,
produced by Xenorhabdus nematophila [22, 23], are the
only bacteriocins characterised to structural level. Bacte-
riocins have also been isolated from Xenorhabdus bovie-
nii and Xenorhabdus beddingii, but they have not been
fully characterised [24].
Gualtieri and co-workers [16] identified five lysine-rich
PAX peptides from X. nematophila F1/1 with strong an-
tifungal activity against Fusarium oxysporum and several
plant pathogenic fungi. Fuchs et al. [25] identified an-
other 13 lysine-rich PAX peptides produced by X. nema-
tophila HGB081. The PAX peptides have an identical
backbone structure, with cyclization occurring between
the ε-amino group of Lys3 and the C-terminus. Accord-
ing to NMR studies, the fatty acids in PAX peptides
from X. nematophila F1/1 are iso-branched [26], whilst
those of X. nematophila HGB081 are straight-chain fatty
acids [25]. Three NRPS genes (paxA, paxB and paxC)
encode biosynthesis of the PAX peptides [25]. PAX pep-
tides have antifungal and antibacterial activity, but they
are not cytotoxic towards insects [25, 26].
The antimicrobial compounds are generally used in
combination with the associated nematodes as biological
control agents in the agricultural industry [26–30]. A
number of antimicrobial compounds produced by
Xenorhabdus spp. have been patented [31–37]. For the
first time we describe a number of PAX lipopeptides
from the A-group and xenocoumacin that are co-
produced by Xenorhabdus khoisanae SB10.
Results and discussion
Xenorhabdus bacteria are known to produce various
antimicrobial compounds, but it is a highly neglected
antimicrobial source that has not been exploited to its
full potential. Although many genes relevant to anti-
microbial compound biosynthesis have been identified in
Xenorhabdus spp., the isolation, purification, identifica-
tion and characterisation of antimicrobial compounds
have not been done for all species belonging to this
genus. Our antiSMASH [38] analysis of the genome of
X. khoisanae SB10 revealed the presence of the xenocou-
macin biosynthetic gene cluster and an APE Ec gene
cluster (Fig. 1). The APE Ec gene cluster is widely dis-
tributed amongst prokaryotes and is related to secondary
metabolites such as aryl polyenes [39]. Identification of
the four modules coding for the PAX synthetase com-
plex in the genome of X. khoisanae SB10 was accom-
plished by using tblastx (Table 1). This study, therefore,
focussed on the first isolation and confirmation that spe-
cific antimicrobial compounds are indeed produced by
X. khoisanae SB10. The following section describes the
purification and characterisation of a selection of anti-
microbial compounds from X. khoisanae SB10 cultures.
A summary of the UPLC-MS data and identification of
the compounds in the antimicrobial fractions are pre-
sented in Table 2. Detailed analysis utilising ESMS,
UPLC-MS and MSe data on these fractions can be found
in the Additional file 1 section.
The first chromatography of the SPC active fractions
on 15 RPC resin by FPLC yielded fraction A1 with
broad-spectrum antimicrobial activity (Fig. 2a). The SPC
A1 fraction was shown to have broad-spectrum activity
towards the four target organisms (B. subtilis, E. coli and
C. albicans), as well as retaining activity after heating at
121 °C for 20 min (results not shown). The latter result
indicated marked heat stability of the antimicrobial com-
pounds and eliminated activity related to labile, or vola-
tile compounds and proteins such as proteases. The A1
fraction was further separated with C18-HPLC into seven
peaks (Fig. 2b). Fractions B, D and G showed strong UV
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absorption (Fig. 2b), suggesting that they did not only
contain PAX peptides, but also xenocoumacin and
breakdown products. Antimicrobial activity was ob-
served in fractions A to G (Fig. 2b) and is shown in
Fig. 3. We first focused on the three major UV-
absorbing fractions, B, D and G, as well as C and F (Fig.
2b), for further analysis using high resolution UPLC-MS
and UPLC-MSe (or MS/MS) analyses (refer to Add-
itional file 1 and Table 2).
The major UPLC-MS peak observed in fraction B con-
tained a small compound with a yellow colour (absorp-
tion maximum at 314 nm) and a monoisotopic Mr of
406.2104 (Fig. 4b and c, insert shows UV-spectrum).
The UPLC-MSe analysis of the peak, containing its mo-
lecular ion with m/z 407.2176 at 4.27 min, yielded six
mayor ions (Fig. 5a). The compound was identified as
xenocoumacin 2 (expected m/z = 407.2182) based on the
characteristic fragmentation pattern. The ion with m/z
250.1428 (Fig. 5a) represents the benzopyran-1-one frag-
ment (expected m/z = 250.1443), while the ion with m/z
158.0788 (Fig. 5a) correlates to the remaining fragment
with pyrrolidine as R group (expected m/z = 158.0817)
[37]. Ions with m/z 176.0699, 190.0849, 215.1058 and
232.1324 (Fig. 5b) are the hydration and dehydration
products of the two main fragments with m/z
158.0788 and 250.1428 (Fig. 5b). This identification of
a xenocoumacin produced by X. khoisanae SB10, was sup-
ported by antiSMASH [39] results of 100% similarity be-
tween the genome of strain SB10 and the xenocoumacin
biosynthetic gene cluster (refer to Fig. 1).
Fraction B also contained an earlier eluting peak at
2.90 min (refer to Fig. 4a) of a larger compound with m/
z 1052.7948 (Mr = 1051.7870). The fragmentation pat-
tern of the ion with m/z 1052.7948 showed a neutral loss
of 128.09 from the major fragments, which is indicative
of the loss of multiple Lys-residues from a peptide chain.
The majority of ions with a neutral fragment loss also
had resultant dehydration products. This dehydration is
the consequence of a fragmentation reaction at the C-
terminal of a Lys residue that leads to cyclisation in
which the amino group of the Lys side chain partici-
pates, similar to fragmentation reactions found for
ornithine-containing peptides [40]. Ions with m/z
129.1015 and 84.0799 also maps to Lys and its immo-
nium ion. The ion spectrum of m/z 1052.7948 and pro-
posed fragmentation pattern is presented in Fig. 6. From
this spectrum we were able to map the sequence to a
Lys-rich lipopeptide from the PAX peptide group. This
particular peptide was identified as PAX1’ with the R
group as (3R)-3-hydroxytetradecanoyl coupled to Gly-
Lys2-cyclo(Lys4) with an expected Mr of 1051.7845 (refer
to Fig. 6 for structure). Although fraction B did not show
Fig. 1 AntiSMASH results presenting the similarity between the genome of X. khoisanae SB10 and biosynthetic gene clusters of Thiomarinol (A),
Zeamine (B), Xenocoumacin (C), Lysobactin (D), APE Ec (E), Xenoamicin (F), Safracin (G), Taxlllaid (H) and Acinetobactin (I)
Table 1 Identification of the four modules coding for the PAX synthetase complex in the genome of X. khoisanae SB10
Gene Protein
product
Synthetase
Protein
Presumed
function
Position on
Chromosome
Identity (%) Positivity (%) Origin Accession
number
xcn1_2784 PaxT XpsD ABC-transporter Node 4–50,691 to 52,328 76 (416/549) 88 (487/549) X. bovienii SS-2004 CBJ81280.1
xcn1_2783 PaxA XpsA NRPS Node 4–52,788 to 56,036 62 (678/1098) 76 (836/1098) X. bovienii SS-2004 CBJ81279.1
xcn1_2782 PaxB XpsB NRPS Node 4–66,118 to 76,893 63 (2265/3614) 76 (2747/3614) X. bovienii SS-2004 CBJ81277.1
xcn1_2781 PaxC XpsB NRPS Node 4–56,079 to 66,107 69 (2307/3356) 81 (2733/3356) X. bovienii SS-2004 CBJ81278.1
Dreyer et al. BMC Microbiology          (2019) 19:132 Page 3 of 11
high activity against E. coli Xen 14, high activity was re-
corded against all other target strains when purified
PAX1’ and xenocoumacin were combined in a 1:1 ratio
(Fig. 3). This result warrants further investigation to de-
termine if the activity between PAX peptides and small
water soluble xenocoumacins are synergistic.
With the identification of the PAX1’ peptide there was
a high probability of other PAX peptides in the HPLC
fractions. In fraction C two more PAX peptides were
found, namely a PAX peptide (m/z 1070.8091) which
correlated to a linear analogue of PAX1’ (denoted
PAX1’L) and a novel PAX peptide from the A group at
m/z 1078.8119, that correlated to a PAX7 with an enoyl
group in the lipid chain, denoted PAX7E1. This putative
identification was done from the accurate Mr, fragmenta-
tion pattern of the peptide moiety (refer to Additional
file 1) and the fact that it eluted just before PAX7. This
elution pattern correlated very well with that of PAX1’
and its 7-enoyl analogue PAX5 (see discussion below
and Table 2). As there is already this identified 7-enoyl
analogue in the PAX group, it is possible PAX7E1 is also
a 7-enoyl analogue. We were, however, not able to con-
firm the structure of the R group with our in-analysis
MSe methodology, as the CID energy only released the
lipid moiety and limited fragmentation was achieved.
Fraction D contained PAX3’ (m/z 1066.8097) and frac-
tion F contained PAX7 (m/z 1080.8286). This fraction
also contained UV absorbing compounds (refer to Fig. 2)
that are possibly the result of xenocoumacin breakdown
(detected compounds with m/z 250.2162, 268.2263,
270.2425, 286.2369). The high PAX7 concentration in
fraction F led to UPLC peak broadening, possibly due to
the aggregation of this lipopeptide. Although PAX7 was
the major compound in fraction F, this fraction also con-
tained other PAX-like peptides. Two low abundance
peptides with different elution times, but with the same
m/z as PAX7E1 with a putative double bond (enoyl) in
lipid chain, were observed at 3.71 and 3.88 min (m/z
1078.8096 and m/z 1078.8096, denoted PAX7E2 and
PAX7E3). PAX7E2 displayed similar peptide chain frag-
ments to that of PAX7 and PAX7E1, suggesting that the
difference in elution time may or due to the position of
the putative double bound in the lipid chain (refer to
Additional file 1). PAX7E3 co-eluted with various com-
pounds, so the fragmentation pattern was inconclusive
although many similar Lys derived fragments were ob-
served. Alternatively, it could be that PAX7E2 and
PAX7E3 elutes later than PAX7E1 due to aggregation
with PAX7 and other compounds, rather than structural
differences. A peptide with m/z 1054.8090 co-eluted
with the PAX7 peptide. From the accurate Mr it was de-
rived that this peptide could be a linear PAX1’ without a
hydroxyl-group (denoted PAX1’L-DH), but the structure
remains unconfirmed due to the co-elution. Fraction G
contained a number of PAX peptides, namely PAX5 (m/
z 1050.7723), PAX1’ (m/z 1052.7936), PAX7 (m/z
1080.8280) and PAX8 (m/z 1106.8412). The fact that the
same PAX peptides eluted in more than one fraction is
Table 2 Summary of the antimicrobial compounds in the three main absorbing fractions that were identified using UPLC-MS and
UPLC-MSe. PAX peptide identities and names are from Fuchs et al. [32]
Fraction UPLC Rt (min) m/z of major [M + H]+ Compound Mr
a Theoretical Mr
b Mass error (ppm)c Proposed compound identity
B 4.27 407.2182 406.2104 406.2104 0.0 Xenocoumacin 2 (C21H30N2O6)
2.93 1052.7948 1051.7870 1051.7845 2.4 PAX1’ (C14H27O2)GK6
C 3.18 1078.8119 1077.8041 1077.8001 3.7 PAX7E1* (C16H29O2)GK6
3.42 1070.8091 1069.7921 1069.7951 −2.8 PAX1L* (C14H29O3)GK6
D 3.29 1066.8097 1065.7965 1065.8001 −3.4 PAX3’ (C15H29O2)GK6
F 3.47 1054.8115 1053.8012 1053.8001 1.0 PAX1L-DH* (C14H29O2)GK6
3.32, 3.47# 1080.8286 1079.8191 1079.8158 3.1 PAX7 (C16H31O2)GK6
3.71 1078.8096 1077.8002 1077.8001 0.1 PAX7E2* (C16H29O2)GK6
3.88 1078.8070 1077.7979 1077.8001 −2.0 PAX7E3* (C16H29O2)GK6
G 2.51 1050.7723 1049.7623 1049.7688 −6.2 PAX5 (C14H25O2)GK6
2.90 1052.7936 1051.7821 1051.7845 2.3 PAX1’ (C14H27O2)GK6
3.57 1080.8280 1079.8161 1079.8158 0.3 PAX7 (C16H31O2)GK6
3.83 1106.8412 1105.8294 1105.8314 −1.8 PAX8 (C18H33O2)GK6
aExperimental monoisotopic Mr of compound was calculated using the TOF transform or MaxEnt3 function in the MassLynx 4.01 software package
bTheoretical monoisotopic Mr of compound was calculated from accurate monoisotopic Mr of Lys =128.09496 and Gly = 57.02146, and monoisotopic Ar of
O =15.9949146; H=1.0078250, N=14.0030740 and C=12.0000000
cMass error in parts per million (ppm) = 106×{Mr (theoretical) - Mr (experimental)}/ Mr (theoretical)
#Early elution of broad peak, fronting and tailing due to aggregation at high concentration
*Putative identification as PAX peptides from peptide moiety fragments and accurate mass determination, E denotes an enoyl group, L denotes linear, DH
denotes dehydroxylated, structure of R-group was not elucidated
Refer to Additional file 1 for UPLC-MS, ESMS and MS/MS data on all the compounds
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possibly due to the formation of hetero-oligomers by
the different lipopeptides, leading to elution at differ-
ent acetonitrile concentrations during reverse phase
chromatography. As in fraction D, fraction G also
contained some UV absorbing compounds (refer to
Fig. 2) that are possibly the result of xenocoumacin
breakdown. Examples of the UPLC-MS chromato-
grams and spectra of the five most abundant PAX
peptides are presented in Fig. 7. The primary struc-
tures of the known PAX peptides that were found in
this study are given in Fig. 8. We were able to con-
firm the peptide sequence of most of the identified
PAX peptides with our UPLC-MSe procedure, except
those that were found in very low concentrations.
Similar fragment patterns to that depicted in Fig. 5
for PAX1’ were observed for the PAX peptides dis-
cussed above (refer to Additional file 1). This discov-
ery and identification of the PAX lipopeptides were
supported by the identification of the four modules
coding for the PAX synthetase complex in the genome of
X. khoisanae by our tblastx study (refer to Table 1).
Conclusions
It was not surprising to discover the production of vari-
ous antimicrobial compounds by X. khoisanae due to
the Xenorhabdus-Steinernema-insect host tripartite
interaction [1]. The known PAX peptides have only been
isolated from X. nematophila, however, this is the first
report of PAX peptides produced by X. khoisanae. PAX
lipopeptides were first characterised by Gaulteri et al.
[16] and to date 13 unique PAX peptides have been re-
ported [34]. Our UPLC-MS and MSe analyses and iden-
tification of PAX peptides and compounds in the
antimicrobial complex of X. khoisanae SB10 have not
been exhaustive, because of the complexity of many frac-
tions containing labile compounds or unresolved com-
pounds. There are certainly more antimicrobial compounds
to discover in this strain’s natural antimicrobial complex in
Fig. 2 Representative chromatograms depicting the isolation of antimicrobial fractions from the X. khoisanae SB10 culture extracts. a Separation
of SPC active fractions on 15 RPC resin by FPLC, with a linear gradient of 10 to 55% (v/v) acetonitrile containing 0.1% (v/v) TFA. b C18 HPLC
chromatography of the fraction A1 in graph A (FPLC active fraction). A linear gradient from 25 to 45% acetonitrile containing 0.1% TFA
was used. The peak fractions denoted A-G in graph B displayed antimicrobial activity
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future studies, such as other xenocoumacins, xenorhabdins
and compounds from the aryl polyene group, as indicated
by the detection of the APE Ec biosynthetic complex (refer
to Fig. 1). Because we consistently found the PAX lipopep-
tides and xenocoumacin in all the X. khoisanae SB10 cul-
ture extracts, we focused in this study on these
compounds. Possible metabolites and degradation products
related to the xenocoumacins were observed in some frac-
tions (D and G), but after in-depth analysis of all the chro-
matographic fractions using UPLC-MS only one intact
xenocoumacin, namely xenocoumacin 2, was identified in
fraction B. It is possible that other xenocoumacins were
also produced, but that the more labile compounds were
lost during purification in a highly acidic environment. We
were, however, able to identify five known Lys-rich lipopep-
tides from the PAX A-group with PAX1’ and PAX7 being
the most abundant. We also discovered two putative linear
PAX analogues, which could possibly be metabolic precur-
sors of PAX1’. PAX7 could be related to the three unknown
PAX peptides with the same Mr of 1077.80 but different re-
tention on a reverse phase matrix. From their Mr, fragmen-
tation patterns and UPLC elution behaviour we putatively
classified the three peptides as enoyl-derivatives of PAX7.
We were, however, unable to confirm the R-group because
of low abundance and co-elution, as well as limited frag-
mentation of the R-group in MSe mode.
This study is the first to identify both the PAX pep-
tides and a xenocoumacin in the antimicrobial complex
of a Xenorhabdus species, as well as the first study on
the antimicrobial complex of the Southern African X.
khoisanae SB10. This report also highlights the natural
tendency of Xenorhabdus species to produce antimicro-
bial complexes consisting of small antibiotics and AMPs.
With the rising antibiotic resistance it may be wise to
consider combining AMPs and small antibiotics, mim-
icking Xenorhabdus-type antimicrobial complexes.
Methods
Bacterial strains, growth media and growth conditions
Xenorhabdus khoisanae SB10 was maintained on NBTA
[41], consisting of nutrient agar supplemented with bro-
mothymol blue (0.025%, w/v) and TTC (0.004%, w/v).
Incubation was at 30 °C. Bacillus subtilis subsp. subtilis
BD170, Escherichia coli Xen 14 and Candida albicans
CAB 392 were used as targets in the testing for anti-
microbial activity. The bacteria and yeast were incubated
at 37 °C. Bacteria were cultured on Brain Heart Infusion
agar (Biolab Diagnostics, Gauteng, South Africa) and C.
albicans on Potato Dextrose Agar (PDA, Biolab Diag-
nostics).
Isolation of antimicrobial compounds
XAD-16 beads were activated by treating with 80% iso-
propanol containing 0.1% (v/v) TFA and added to TSB.
After 30 min at 4 °C on an orbital shaker (100 rpm), the
XAD-16 beads were removed and the medium auto-
claved. X. khoisanae SB10 was inoculated into 5 ml un-
treated TSB and incubated at 26 °C for 24 h on a
rotating wheel. The culture was added to 5 g activated
XAD-16 beads, spread-plated onto XAD-16-treated TSB
agar in petri dishes with a diameter of 135 mm and incu-
bated at 26 °C for 96 h. Beads were collected from the
plates and washed with sterile deionised water to remove
the cells. Water was removed from beads by vacuum
suction. The beads were washed with 150 mL 30% (v/v)
ethanol for 15 min at 4 °C on an orbital shaker (100 rpm)
. Ethanol was removed by vacuum suction and the beads
were washed with sterile deionised water. Amphipathic
Fig. 3 Antimicrobial activity of the factions collected (fractions B, C, D, F and G) and the combined activity of purified xenocoumacin 2 (m/z 407)
and PAX1’1 (m/z 1052) from the compound library of the Department of Microbiology. Growth inhibition is observed as zones surrounding the
wells. Activity BD170 = Bacillus subtilis subsp. subtilis, Xen 14 = Escherichia coli and CAB 392 = Candida albicans
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compounds were liberated from the beads, using
70% (v/v) isopropanol containing 0.1% (v/v) TFA
(isopropanol-TFA). The eluent was filtered through a
0.45 μM cellulose nitrate filter and the isopropanol
removed by using a rotary evaporator (RotaVapor® R-
114, Büchi).
Purification of antimicrobial compounds
The concentrated eluent was subjected to reverse phase
chromatography on a 10ml Sep-Pak C18 column (Waters,
Milford, USA) on Perista Pump SJ-1211 (Chromatograph
ATTO corporations, Tokyo, Japan). The column was
washed with deionised water and compounds eluted by
using a stepwise gradient ranging from 10 to 70% (v/v)
isopropanol in analytical quality water with constant 0.1%
TFA (v/v) in solvent system. The gradient was created
with 10% increments per 10min at 2mL/minute flowrate.
The fractions (denoted SPC fractions) were dried by rotary
evaporation and tested for antimicrobial activity using the
agar-well diffusion assay as described elsewhere.
Active SPC fractions were loaded onto a HiScale col-
umn (100 × 16 mm) packed with 15 RPC resin (GE
Healthcare, South Africa) fitted to fast protein liquid
chromatography (FPLC, ÄKTA purifier, GE Healthcare,
South Africa). Fractions were eluted by a linear gradient
of 10 to 55% B over 30 min, at a flow rate of 2.5 ml/min
(A: analytical quality water containing 0.1%, v/v, TFA; B:
HPLC grade acetonitrile containing 0.1%, v/v, TFA).
Readings were recorded at 254 nm. Fractions were tested
for antibacterial activity against B. subtilis subsp. subtilis
BD170, using the agar-well diffusion assay as described
elsewhere.
Fractions with antimicrobial activity collected from
the ÄKTA purifier (FPLC active fractions) were ly-
ophilized, resuspended in 50% (v/v) acetonitrile,
loaded onto a Discovery BIO Wide Pore C18 HPLC
column (10 μm, 250 × 10 mm; Sigma-Aldrich) and
eluted by using a linear gradient (25 to 45%) of
eluent B over 28 min at a flow rate of 2.0 ml/min.
Further separation was on a Surveyor plus HPLC
(Thermo Fisher Scientific, Waltham, Massachusetts,
USA). Readings were recorded at 254 nm. Peak frac-
tions were collected, dried and the antimicrobial ac-
tivity tested as described elsewhere.
Fig. 4 The UPLC profiles of fraction B collected from C18-HPLC (refer to Fig. 2 b). The top chromatogram (a) shows the base peak intensity mass
chromatogram of fraction B and the middle chromatogram (b) the mass extracted chromatogram for the molecular ion with m/z 407.217 at 30
ppm tolerance. The bottom chromatogram (c) shows the spectrophotometric profile at 314 nm and the insert shows the UV spectrum of the
peak at 4.23 min
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Fig. 5 ESI-MS and CID spectra (generated via MSe type analysis) of the main component at 4.23 in fraction B, namely xenocoumacin 2. The
component mass spectrum of xenocoumacin 2 (structure insert) is shown in the top spectrum (a) and fragmentation product ion spectrum is
shown in the bottom spectrum (b). The two main fragments are indicated on the xenocoumacin 2 structure. Refer to the text for the discussion
of the fragmentation of xenocoumacin 2
Fig. 6 Representative CID spectrum over m/z 50–1050 of PAX1’ with intact molecular ion at m/z = 1052.79. CID analyses were performed over a
CE gradient from 20 to 60 eV at a CV of 15 V. The two structures above the spectrum show the fragments that would lead to the 513.4 and 668.5
product ions and their subsequent fragmentation. The R group for PAX1’ is (3R)-3-hydroxy tetradecanoyl and the side-chain of Lys3 links up to
the carboxyl group of Lys7 to form the ring structure
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Analysis of fractions with ultra-performance liquid
chromatography and electrospray ionization mass
spectrometry
Fractions with antimicrobial activity collected from the
HPLC were subjected to UPLC, using an Aquity UPLC™
linked to a Waters Synapt G2 Mass Spectrometer (Wa-
ters Corporation, Miliford, USA). This was denoted
UPLC-MS. Samples were prepared in 50% acetonitrile in
water (1:1, v/v) at a concentration 200–1000 μg/mL.
Samples were injected at 1–5 μl via Waters Acquity
UPLC™ and chromatography was monitored in positive
ESI mode and via PDA (230–400 nm). Separation of the
components in each HPLC fraction were done on an
Acquity UPLC® HSS T3 C18 column (1.8 μm particle
size, 2.1 × 150 mm, Waters Corporation, Dublin, Ireland)
. Chromatography was done with analytical quality water
modified with 0.1% (v/v) formic acid as eluent A and
acetonitrile modified with 0.1% (v/v) formic acid as
eluent B. The gradient developed at flow rate of 300 μl/
min was as follows: 0 to 0.5 min at 40% B, linear gradi-
ent from 40 to 95% B from 0.5 to 11min and 11 to 14
min at 95% B. The rest of the instrument settings for the
UPLC-MS mode were as follows: cone voltage set at 15
V, a capillary voltage of 2.5 kV, cone voltage of 15 V, ex-
traction cone voltage 4 V, source temperature of 120 °C,
desolvation gas of 650 l/h and desolvation temperature
of 275 °C. Data were collected in positive mode by scan-
ning through m/z = 100 to 2000 in centroid mode at a
rate of 0.2 scans/sec.
High resolution collisionally induced dissociation
(CID) analyses were done in the MSe mode (tandem MS
or MS/MS) during the UPLC-MS and monitored on a
second MS channel. CID were done at a collision energy
gradient of 20 to 60 eV at 1 s MS/MS scan time. Data
were collected in the second mass analyser (MS2)
through m/z = 40 to 1500 in centroid mode. The rest of
the instrument settings were as described above. To en-
sure reliable high-resolution MS data, the MS instruments
Fig. 7 UPLC-MS profiles (left panel) and ESI-MS spectra (right panel) of the five major PAX lipopeptides that were detected in the antimicrobial
fractions of the X. khoisanae SB10 culture extracts
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were calibrated with sodium formate. Single point lock
spray using leucine encephalin (m/z = 556.2771) as
calibrant was used during analysis to compensate for
any m/z drift.
Antimicrobial activity of fractions from purification
SPC active fractions were suspended in analytical quality
water, containing 0.1% (v/v) TFA to 350 mg/ml. The
antimicrobial activity of fractions was tested using an
agar-well diffusion assay in a micro well titre plate. In
short, the appropriate growth media containing 1.0% (w/
v) agar was seeded with a dense 12-h-old culture of B.
subtilis subsp. subtilis BD170, E. coli Xen 14 (1.0%, v/v)
or C. albicans CAB 392 (1.0%, v/v). Wells were made
into the agar and 15 μL of each fraction dispensed into a
well. Plates were incubated for 24 to 48 h at 37 °C. A
clear zone surrounding the well indicated activity. Ana-
lytical quality water, containing 0.1% (v/v) TFA, was used
as negative control. Ciprofloxacin was used as positive
control for B. subtilis subsp. subtilis BD170 and E. coli
Xen 14 and amphotericin B for C. albicans CAB 392.
Temperature stability
SPC active fractions of 350mg/mL were prepared in MilliQ
water, containing 0.1% (v/v) TFA. The suspension was auto-
claved for 20min and tested for antimicrobial activity
against B. subtilis subsp. subtilis BD170, using the agar-well
diffusion assay as described elsewhere. Plates were incu-
bated at 37 °C for 24 h. The diameter of growth inhibition
zones was recorded and compared to controls. This was
done by using the software program ImageJ (v. 1.48).
Additional file
Additional file 1: Detailed mass spectrometric analysis of the
chromatographic fractions of X. khoisanae extracts. (PDF 471 kb)
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